A Phase III, Open-labelled, Randomised Study of Neoadjuvant Docetaxel+Oxaliplatin+S-1 (DOS) + Surgery + Adjuvant S-1 Versus Surgery + Adjuvant S-1 in Patients With Resectable Advanced Gastric Cancer.

Trial Profile

A Phase III, Open-labelled, Randomised Study of Neoadjuvant Docetaxel+Oxaliplatin+S-1 (DOS) + Surgery + Adjuvant S-1 Versus Surgery + Adjuvant S-1 in Patients With Resectable Advanced Gastric Cancer.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Docetaxel (Primary) ; Oxaliplatin (Primary) ; Gimeracil/oteracil/tegafur
  • Indications Gastrointestinal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PRODIGY
  • Sponsors Sanofi
  • Most Recent Events

    • 28 Feb 2017 Status changed from recruiting to active, no longer recruiting.
    • 13 Jul 2016 Planned patient number changed from 530 to 640.
    • 13 Jul 2016 Planned End Date changed from 1 Jul 2019 to 1 Jan 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top